Association of CCR2-CCR5 Haplotypes and CCL3L1 Copy Number with Kawasaki Disease, Coronary Artery Lesions, and IVIG Responses in Japanese Children
暂无分享,去创建一个
Teiji Akagi | Susumu Furukawa | Jane C. Burns | J. Burns | A. Hata | S. Ahuja | M. Mamtani | C. Shimizu | Akira Hata | Yoshihiro Onouchi | T. Akagi | Chisato Shimizu | Weijing He | Sunil K. Ahuja | Tomoyo Matsubara | Manju Mamtani | Y. Onouchi | A. Fujino | Akihiro Fujino | S. Furukawa | T. Matsubara | Weijing He
[1] Kei Takahashi,et al. Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease , 2005, Pediatrics international : official journal of the Japan Pediatric Society.
[2] E. Silverman,et al. Evidence for RANTES, monocyte chemotactic protein-1, and macrophage inflammatory protein-1 beta expression in Kawasaki disease. , 1997, The Journal of rheumatology.
[3] B. Rovin,et al. The Influence of CCL 3 L 1 Gene – Containing Segmental Duplications on HIV-1 / AIDS Susceptibility , 2009 .
[4] M. Hammer,et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1α: Impact on the epidemiology of the HIV-1 pandemic , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[5] J. Newburger,et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. , 1998, The Pediatric infectious disease journal.
[6] S. Colan,et al. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. , 1998, The Journal of pediatrics.
[7] Jane C Burns,et al. Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. , 2005, The Journal of infectious diseases.
[8] A. J. Valente,et al. Evolution of Human and Non-human Primate CC Chemokine Receptor 5 Gene and mRNA , 2000, The Journal of Biological Chemistry.
[9] T. Matsuishi,et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. , 2006, The Journal of pediatrics.
[10] T. Onodera,et al. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. , 2000, The Journal of pediatrics.
[11] K. Matsushima,et al. Dramatic decrease of circulating levels of monocyte chemoattractant protein‐1 in Kawasaki disease after gamma globulin treatment , 1999, Journal of leukocyte biology.
[12] K. Yamada,et al. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin , 2004, Archives of Disease in Childhood.
[13] S. Kurotobi,et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment , 2006, European Journal of Pediatrics.
[14] Yusuke Nakamura,et al. Japanese population structure, based on SNP genotypes from 7003 individuals compared to other ethnic groups: effects on population-based association studies. , 2008, American journal of human genetics.
[15] Kejun Liu,et al. PowerMarker: an integrated analysis environment for genetic marker analysis , 2005, Bioinform..
[16] A. Morikawa,et al. [Risk stratification and prediction of resistance to intravenous immunoglobulin in Kawasaki disease]. , 2008, Nihon rinsho. Japanese journal of clinical medicine.
[17] B. Neel,et al. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. , 2007, Immunity.
[18] Naoko Kinukawa,et al. Association of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor Gene Polymorphisms with Coronary Artery Lesions of Kawasaki Disease , 2004, Pediatric Research.
[19] J. Van Damme,et al. Macrophage inflammatory protein-1. , 2002, Cytokine & growth factor reviews.
[20] Yu-Lung Lau,et al. Inflammatory Gene Polymorphisms and Susceptibility to Kawasaki Disease and Its Arterial Sequelae , 2008, Pediatrics.
[21] S. Kikuchi,et al. C–C chemokine receptor 2 gene polymorphism in Japanese patients with multiple sclerosis , 2003, Journal of Neuroimmunology.
[22] Jong-Keuk Lee,et al. The CCR5 (−2135C/T) Polymorphism may be Associated with the Development of Kawasaki Disease in Korean Children , 2008, Journal of Clinical Immunology.
[23] Chan-Wook Woo,et al. Predictive risk factors for coronary artery abnormalities in Kawasaki disease , 2007, European Journal of Pediatrics.
[24] Tomio Kobayashi,et al. Prediction of Intravenous Immunoglobulin Unresponsiveness in Patients With Kawasaki Disease , 2006, Circulation.
[25] M. Ballow. Clinical and investigational considerations for the use of IGIV therapy. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[26] B. Rovin,et al. CCL3L1 gene-containing segmental duplications and polymorphisms in CCR5 affect risk of systemic lupus erythaematosus , 2007, Annals of the rheumatic diseases.
[27] M. Baggiolini,et al. CCR5 is characteristic of Th1 lymphocytes , 1998, Nature.
[28] P. Fietta,et al. The effector T helper cell triade. , 2009, Rivista di biologia.
[29] J. Guzman-Cottrill,et al. Recent developments and controversies in Kawasaki disease. , 2004, Minerva pediatrica.
[30] J. Newburger,et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. , 2008, The Journal of pediatrics.
[31] Y. Kawakami,et al. The role of the C-C chemokine receptor 2 gene polymorphism V64I (CCR2-64I) in sarcoidosis in a Japanese population. , 1999, American journal of respiratory and critical care medicine.
[32] M. Adams,et al. Recent Segmental Duplications in the Human Genome , 2002, Science.
[33] T Enright,et al. Kawasaki syndrome. , 1990, Annals of allergy.
[34] T. Ueland,et al. Chemokines and Cardiovascular Risk , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[35] P. O’Connell,et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression , 1998, Nature Medicine.
[36] R. Sittiwangkul,et al. Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease. , 2006, Singapore medical journal.
[37] A. Billiau,et al. How interferon-gamma keeps autoimmune diseases in check. , 2008, Trends in immunology.
[38] L. Jonides,et al. Kawasaki disease. , 1994, Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners.
[39] R. Welch,et al. Polymorphisms in chemokine receptor genes and susceptibility to Kawasaki disease , 2007, Clinical and experimental immunology.
[40] Y. Kohno,et al. Monocyte chemoattractant protein 1 gene regulatory region polymorphism and serum levels of monocyte chemoattractant protein 1 in Japanese patients with Kawasaki disease. , 2001, Arthritis and rheumatism.
[41] T. Asano,et al. Expression of IL‐8 in Kawasaki disease , 2000, Clinical and experimental immunology.
[42] D. Conrad,et al. Global variation in copy number in the human genome , 2006, Nature.
[43] Yusuke Nakamura,et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms , 2008, Nature Genetics.
[44] L. Barcellos,et al. Gene copy number regulates the production of the human chemokine CCL3‐L1 , 2002, European journal of immunology.
[45] M. Hara,et al. A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with Kawasaki disease. , 2003, The Journal of pediatrics.
[46] R. Cantor,et al. Family-based association analysis implicates IL-4 in susceptibility to Kawasaki disease , 2005, Genes and Immunity.
[47] Ogawa,et al. Expression of Monocyte Chemoattractant Protein‐1 in Kawasaki Disease: The Anti‐Inflammatory Effect of Gamma Globulin Therapy , 2000, Scandinavian Journal of Immunology.
[48] J. Ottenkamp,et al. The involvement of Fc gamma receptor gene polymorphisms in Kawasaki disease , 2006, Clinical and experimental immunology.
[49] S. Shulman,et al. New developments in the search for the etiologic agent of Kawasaki disease , 2007, Current opinion in pediatrics.
[50] B. Neel,et al. FcγRIII-Dependent Inhibition of Interferon-γ Responses Mediates Suppressive Effects of Intravenous Immune Globulin , 2007 .
[51] Paul D. Mitchell,et al. Coronary Artery Involvement in Children With Kawasaki Disease: Risk Factors From Analysis of Serial Normalized Measurements , 2007, Circulation.
[52] L. Benson,et al. Outcome of coronary artery aneurysms after Kawasaki disease. , 1992, The Journal of pediatrics.
[53] Yoshikazu Nakamura,et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition) , 2005, Pediatrics international : official journal of the Japan Pediatric Society.
[54] Norishige Yoshikawa,et al. A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease. , 2005, The Journal of pediatrics.
[55] Lei Wan,et al. Influence of interleukin 18 promoter polymorphisms in susceptibility to Kawasaki disease in Taiwan. , 2008, The Journal of rheumatology.
[56] J. Anaya,et al. Association of copy number variation in the FCGR3B gene with risk of autoimmune diseases , 2010, Genes and Immunity.
[57] K. Yoon,et al. Risk Factors for Failure of Initial Intravenous Immunoglobulin Treatment in Kawasaki Disease , 2008, Journal of Korean medical science.